Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00003665 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Melanoma (Skin)

Interventions

BIOLOGICAL: dendritic cell-MART-1 peptide vaccine
BIOLOGICAL: gp100 antigen
BIOLOGICAL: therapeutic tumor infiltrating lymphocytes
BIOLOGICAL: tyrosinase peptide

Sponsor

National Cancer Institute (NCI)